Neurological

Stroke Recovery: cell-therapy evidence and registered trials

A source-first research page for the exact condition. It does not recommend a cell product, clinic or private treatment.

Registry snapshot

ClinicalTrials.gov returned 110 registered studies for the stored condition/intervention query, including 13 recruiting records, retrieved 2026-08-05T06:02:03+00:00. A registry count does not establish efficacy, approval, relevance or eligibility; inspect each study's design, product, status and inclusion criteria.

Research activity over time

Registration of new studies slowed: 25 newly registered studies in 2021–2025 against 32 in 2016–2020. The first study in this registry query was posted in 2005; the registry now holds 110 in total, of which 13 are recruiting. Counting is by first-posted date, so the series reflects when research was registered — not enrolment, completion or results.

Newly registered Stroke Recovery studies by year
20165
20179
20186
20197
20205
20215
20223
20236
20244
20257
20266

Source: ClinicalTrials.gov API v2, retrieved 2026-08-05. A registration count is not evidence of efficacy, approval or eligibility. Open the exact query ↗

What to verify before interpreting a study or offer

  1. The exact product, cell source, processing, dose and delivery route.
  2. The indication, study phase, comparator, endpoints, status and eligibility criteria.
  3. Whether the proposed use is authorised, part of a registered trial or otherwise investigational.
  4. Provider and manufacturing authorisations, release testing, traceability and adverse-event reporting.
  5. How the proposal compares with current standard care, reviewed by an independent physician.

Sources & further reading

Registry data is a discovery aid, not evidence that a treatment works or is suitable for an individual patient.

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Get an honest assessment